Nearly a year after leaving his position as longtime director of the National Human Genome Research Institute (NHGRI), Eric ...

Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.

If you are wondering whether Illumina's current share price offers fair value or room for mispricing, you are not alone. This article walks through what the numbers actually say about the stock.

Illumina, Inc. has announced that scientists at the Company have sequenced the genome of an anonymous African male (Yoruba from Ibadan, Nigeria), using the Genome Analyzer. Sequencing of this HapMap ...

During the meeting, Steve Barnard, PhD, Illumina’s CTO will provide new details about the company’s constellation mapped read technology. He will be joined by Niall Lennon, PhD, chair and CSO of Broad ...

Illumina, whose EMEA head office is at Granta Park in Cambridge, has released Illumina Connected Multiomics, a powerful cloud ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country. It’s part ...

Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer ...